JP2012515164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515164A5 JP2012515164A5 JP2011545490A JP2011545490A JP2012515164A5 JP 2012515164 A5 JP2012515164 A5 JP 2012515164A5 JP 2011545490 A JP2011545490 A JP 2011545490A JP 2011545490 A JP2011545490 A JP 2011545490A JP 2012515164 A5 JP2012515164 A5 JP 2012515164A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- corneal
- subject
- nerve
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 37
- 210000001519 tissue Anatomy 0.000 claims description 36
- 230000002757 inflammatory effect Effects 0.000 claims description 27
- 102000000589 Interleukin-1 Human genes 0.000 claims description 26
- 210000004087 cornea Anatomy 0.000 claims description 25
- 108010002352 Interleukin-1 Proteins 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 24
- 208000028389 Nerve injury Diseases 0.000 claims description 22
- 230000008764 nerve damage Effects 0.000 claims description 22
- 210000005036 nerve Anatomy 0.000 claims description 19
- 210000001365 lymphatic vessel Anatomy 0.000 claims description 18
- 230000002159 abnormal effect Effects 0.000 claims description 15
- 230000001363 autoimmune Effects 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000036039 immunity Effects 0.000 claims description 12
- 230000006698 induction Effects 0.000 claims description 10
- 230000035168 lymphangiogenesis Effects 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 8
- 206010013774 Dry eye Diseases 0.000 claims description 8
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 8
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 8
- 208000023715 Ocular surface disease Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000000977 initiatory effect Effects 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 239000004055 small Interfering RNA Substances 0.000 claims description 8
- 230000032258 transport Effects 0.000 claims description 7
- 210000001165 lymph node Anatomy 0.000 claims description 6
- 210000004126 nerve fiber Anatomy 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 5
- 230000001537 neural effect Effects 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 206010002329 Aneurysm Diseases 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 4
- 102000013691 Interleukin-17 Human genes 0.000 claims description 4
- 108050003558 Interleukin-17 Proteins 0.000 claims description 4
- 108700011259 MicroRNAs Proteins 0.000 claims description 4
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003172 expectorant agent Substances 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 238000007917 intracranial administration Methods 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 229940066491 mucolytics Drugs 0.000 claims description 4
- 206010069732 neurotrophic keratopathy Diseases 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 230000004321 blink reflex Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000034994 death Effects 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 230000030214 innervation Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 230000008760 nerve sprouting Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000004766 neurogenesis Effects 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 230000003957 neurotransmitter release Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000011514 reflex Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 230000004489 tear production Effects 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 230000007903 penetration ability Effects 0.000 claims 6
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 230000007698 birth defect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000004656 cell transport Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14356109P | 2009-01-09 | 2009-01-09 | |
| US61/143,561 | 2009-01-09 | ||
| PCT/US2010/020646 WO2010081091A2 (en) | 2009-01-09 | 2010-01-11 | Therapeutic compositions for treatment of corneal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515164A JP2012515164A (ja) | 2012-07-05 |
| JP2012515164A5 true JP2012515164A5 (cg-RX-API-DMAC7.html) | 2013-07-25 |
Family
ID=42144303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545490A Pending JP2012515164A (ja) | 2009-01-09 | 2010-01-11 | 角膜障害を処置するための治療組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10117906B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2385839B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012515164A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010203425B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2749537C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010081091A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230776T1 (hr) * | 2010-07-29 | 2023-10-27 | Buzzard Pharmaceuticals AB | Himerni antagonisti receptora il-1 tipa i |
| WO2012103240A2 (en) * | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
| WO2013126599A1 (en) | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Meibomian gland dysfunction |
| WO2013126602A1 (en) | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| WO2014036445A2 (en) * | 2012-08-31 | 2014-03-06 | Johnson Michael R | Novel mucolytic agents |
| JP6450364B2 (ja) | 2013-03-13 | 2019-01-09 | セセン バイオ, インコーポレイテッド | 眼送達のためのキメラサイトカイン製剤 |
| SG11201601291QA (en) | 2013-08-23 | 2016-03-30 | Parion Sciences Inc | Dithiol mucolytic agents |
| JP6377618B2 (ja) * | 2013-08-28 | 2018-08-22 | 千寿製薬株式会社 | 角膜上皮障害治療剤 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| BR112017016067A2 (pt) | 2015-01-30 | 2018-04-03 | Parion Sciences Inc | agentes mucolíticos de monotiol |
| JP2018520986A (ja) | 2015-04-30 | 2018-08-02 | パリオン・サイエンシィズ・インコーポレーテッド | ジチオール粘液溶解剤の新規なプロドラッグ |
| US20180312838A1 (en) * | 2015-10-21 | 2018-11-01 | The Regents Of The University Of California | Modulation of microrna 184 to treat pathological lymphangiogenesis |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| WO2020218488A1 (ja) * | 2019-04-26 | 2020-10-29 | 千寿製薬株式会社 | 眼疾患マーカー |
| CN113350326B (zh) * | 2021-07-28 | 2023-03-17 | 爱尔眼科医院集团股份有限公司 | 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用 |
| KR102883890B1 (ko) * | 2021-11-30 | 2025-11-07 | 한림대학교 산학협력단 | miR-30c-1 발현 수준을 증가시키기 위한 제제를 사용하는 각막 내피 세포 배양 방법 및 각막 내피 세포 질환 치료용 조성물 |
| CN118304388B (zh) * | 2024-04-03 | 2025-02-11 | 南通大学 | Tak1在制备治疗周围神经损伤药物中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0610336B1 (en) | 1991-10-31 | 2002-03-27 | The Victoria University Of Manchester | Treatment of neurological conditions by an interleukin-1 inhibiting compound |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| WO1998022130A1 (en) * | 1996-11-19 | 1998-05-28 | The Schepens Eye Research Institute, Inc. | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| JP3363832B2 (ja) | 1999-05-13 | 2003-01-08 | アルプス電気株式会社 | 薄膜構造体およびその製造方法 |
| US20030104041A1 (en) | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| EP1252895A4 (en) | 2000-01-31 | 2003-04-16 | Santen Pharmaceutical Co Ltd | REMEDIES FOR OPHTHALMIC DISORDERS |
| WO2001057082A2 (en) | 2000-02-03 | 2001-08-09 | Regeneration Technologies, Inc. | Extraction of growth factors from tissue |
| US20010047204A1 (en) * | 2000-03-20 | 2001-11-29 | Medennium, Inc. | Method for determination of a properly sized posterior chamber phakic refractive lens |
| US20020131954A1 (en) | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US20050143333A1 (en) | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| WO2003022213A2 (en) | 2001-09-06 | 2003-03-20 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| US7683165B2 (en) | 2002-02-20 | 2010-03-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
| US6890654B2 (en) | 2002-04-18 | 2005-05-10 | Northwestern University | Encapsulation of nanotubes via self-assembled nanostructures |
| WO2004060911A2 (en) * | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| US20050033694A1 (en) * | 2003-06-03 | 2005-02-10 | United States Postal Service. | System and method for fleet card management |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| US20050023872A1 (en) * | 2003-07-28 | 2005-02-03 | Hetzel Thomas R. | Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion |
| KR100543466B1 (ko) * | 2003-11-13 | 2006-01-20 | 삼성전자주식회사 | 영상 보간 장치 및 방법 |
| GB0404693D0 (en) | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| CA2588449A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| JP4815808B2 (ja) | 2005-01-24 | 2011-11-16 | 三菱電機株式会社 | ロータリ圧縮機 |
| CN102293774A (zh) | 2005-03-31 | 2011-12-28 | 旭硝子株式会社 | 前列腺素F2α衍生物的应用 |
| EP1870099A4 (en) | 2005-04-13 | 2008-07-16 | Ube Industries | PROTECTION AGAINST RETINAL NERVOUS CELLS WITH INDAZOLE DERIVATIVE AS ACTIVE SUBSTANCE |
| US7670849B2 (en) | 2005-04-29 | 2010-03-02 | Henkin Robert I | Method for diagnosing insulin resistance from nasal secretions |
| DE602006009834D1 (de) * | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| KR20110079922A (ko) * | 2006-04-14 | 2011-07-11 | 노파르티스 아게 | 안과 장애 치료를 위한 il-1 항체의 용도 |
| US20080026485A1 (en) * | 2006-04-18 | 2008-01-31 | Wolfgang Hueber | Antibody profiling for determination of patient responsiveness |
| CN101489569A (zh) | 2006-06-12 | 2009-07-22 | 席拉坎有限责任公司 | 眼表面疾病的局部治疗 |
| CA2679588A1 (en) * | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| EP2187900B1 (en) | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| CA2711696C (en) * | 2008-01-09 | 2021-10-26 | Reza Dana | Therapeutic compositions for treatment of ocular inflammatory disorders |
| US20120014970A1 (en) * | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
| US9011861B2 (en) * | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
-
2010
- 2010-01-11 EP EP10700459.0A patent/EP2385839B1/en active Active
- 2010-01-11 CA CA2749537A patent/CA2749537C/en not_active Expired - Fee Related
- 2010-01-11 WO PCT/US2010/020646 patent/WO2010081091A2/en not_active Ceased
- 2010-01-11 US US12/685,510 patent/US10117906B2/en active Active
- 2010-01-11 JP JP2011545490A patent/JP2012515164A/ja active Pending
- 2010-01-11 AU AU2010203425A patent/AU2010203425B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7358221B2 (ja) | 老視を治療するための組成物及び方法 | |
| Awwad et al. | Principles of pharmacology in the eye | |
| JP5886523B2 (ja) | 眼の炎症性障害を処置するための治療組成物 | |
| JP2022502421A5 (cg-RX-API-DMAC7.html) | ||
| JP2011517659A5 (cg-RX-API-DMAC7.html) | ||
| AU2010203425B2 (en) | Therapeutic compositions for treatment of corneal disorders | |
| KR20180014824A (ko) | 눈의 굴절 이상 치료 방법 및 저장 안정성 조성물 | |
| JP7324208B2 (ja) | 近視進行の治療 | |
| US20210299219A1 (en) | Compositions and methods for prevention and treatment of corneal haze and scarring | |
| EP2525793A2 (en) | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| KR20200116953A (ko) | 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 안과 질환의 예방 또는 치료를 위한 의약 | |
| US20120014970A1 (en) | Therapeutic Compositions for Treatment of Corneal Disorders | |
| CA2819616A1 (en) | Methods for treating diseases of the retina | |
| JP2009519232A5 (cg-RX-API-DMAC7.html) | ||
| WO2017043612A1 (ja) | ドライアイ改善剤 | |
| ITMI20110583A1 (it) | Preparazioni oftalmiche a base di pacap (pituitary adenylate cyclase activating polypeptide) al fine di ripristinare la normale funzione visiva nel glaucoma in fase precoce | |
| WO2022259211A1 (en) | Ophthalmic compositions and/or methods for presbyopia, mydriasis and/or ocular discomfort management | |
| JP2005306815A (ja) | 眼障害を予防および/または治療するための眼科用組成物 | |
| JP2019151628A (ja) | 角膜上皮障害治療剤 | |
| Lim | Recent Developments in Glaucoma | |
| Mohamadi et al. | The effect of phacoemulsification with posterior chamber intraocular lens implantation on intraocular pressure and anterior chamber depth |